Bukaan u dhashay Australia ayaa ku guuleystay jawaab celin hore oo cajiib ah iyadoo la adeegsanayo Daaweynta Dual CD19/CD20 CAR-T ee BIOOCUS Medical Group ee loogu talagalay DLBCL-ka soo noqnoqda
Rodney Charles Monger, oo 68 jir ah oo u dhashay dalka Australia, ayaa lagu ogaaday inuu qabo cudurka kansarka maqaarka. Lymphoma-ka Unugga B (DLBCL) saddex sano ka hor. Isagoo raadinaya daryeel sare, wuxuu u jeestay Kooxda Caafimaadka ee BIOOCUS bishii Agoosto 2025. Baaritaan lagu sameeyay qanjidhada limfaha ilmo-galeenka ayaa xaqiijiyay in lymphoma-ka B-cell uu ku dhacay asalka xarunta jeermiska. Immunohistochemistry-gu wuxuu si xooggan u saameeyay CD20, CD19, iyo CD10, iyadoo la muujinayo Bcl-6, Bcl-2 (70%+), iyo c-MYC (60%+). Baaritaanka hidde-sidaha ayaa muujiyay dib-u-habaynta BCL2 ee FISH iyo isbeddellada ku yimid hiddo-sideyaasha EZH2, KMT2D, TNFRSF14, NRAS, iyo TPMT - calaamado cad oo muujinaya muuqaal gardarro ah oo khatar sare leh.
Ka dib markii la siiyay daawada pola oo ay weheliso daawada BTK ee joojisa iyo lenalidomide, oo ay ku xigto daaweynta kiimikada lymphodepletion ee FC, cudurka Mr. Monger wuxuu ahaa mid aan firfircoonayn. Kooxda BIOOCUS Medical Group waxay ku taliyeen daaweyntooda cusub ee unugyada CD19/CD20 CAR-T ee laba-bartilmaameedsan.
Sebteembar 8, 2025, Mr. Monger wuxuu qaatay gelinta unugyada CD19/CD20 ee iswada. Waxaa la yaab leh, ma uusan la kulmin cudurka sii deynta cytokine (CRS) iyo cudurka neurotoxicity-ga ee la xiriira unugyada difaaca jirka (ICANS), taasoo keentay koorso si habsami leh u socota oo ka dhigtay mid deggan oo rajo wanaagsan laga bilaabo maalintii ugu horreysay.
La socodka dhiigga ee hareeraha ayaa diiwaangeliyay ballaarinta unugyada CAR-T oo cajiib ah, taasoo xaqiijisay in si fiican loo farsameeyay loona ballaariyay. Maalintii 4aad ee la geliyay ka dib, unugyada CAR19+ waxay ahaayeen 0.50% unugyada CD3+ T (qiimaha dhammaystiran waa 6.04 × 10⁷/L) iyo unugyada CAR20+ 0.41% (4.96 × 10⁷/L). Maalintii 7aad, CAR19+ wuxuu kor u kacay 1.68% (1.40 × 10⁷/L) iyo CAR20+ ilaa 1.63% (1.36 × 10⁷/L). Maalintii 10aad, CAR19+ wuxuu gaaray 31.43% unugyada CD3+ T (qiimaha dhammaystiran waa 3.13 × 10⁸/L) iyo CAR20+ wuxuu gaaray 32.74% (qiimaha dhammaystiran waa 3.26 × 10⁸/L). Cytometry-ga socodka ayaa sidoo kale muujiyay qaybin dheellitiran oo ku baahsan qaybaha hoose ee CD4+ iyo CD8+ oo leh muuqaal laba-geesood ah oo CAR ah, taasoo muujinaysa awoodda daawaynta ee lagu horumarin karo adkeysiga iyo koritaanka xooggan ee gudaha-nolosha.
Dabagalka ugu dambeeyay (maalintii 10aad), Mr. Monger wuxuu sii wadaa inuu si fiican u shaqeeyo kiliinikada. Wuxuu ku jiraa daawo afka laga qaato oo loogu talagalay oo ay ku jiraan acyclovir, sulfamethoxazole isku dhafan, orelabrutinib, lenalidomide, iyo wakiillo taageero ah, iyadoo si joogto ah loola socdo tirinta dhiigga, shaqada beerka iyo kelyaha, iyo calaamadaha bararka.
Kooxda BIOOCUS Medical Group waxay siiyeen taageero dhammaystiran oo bukaanka ku salaysan, oo ay ku jiraan hoy raaxo leh, cunto nafaqo leh, gargaar gaadiid, iyo la-talin cilmi-nafsi ah oo loogu talagalay Mr. Monger iyo qoyskiisa. Habkan dhammaystiran wuxuu u oggolaaday inuu si buuxda diiradda u saaro soo kabashada.
Kiiska Mr. Monger wuxuu tusaale u yahay awoodda isbeddelka ee daaweynta laba-geesoodka ah ee BIOOCUS Medical Group ee CD19/CD20 CAR-T ee bukaanada qaba DLBCL oo soo noqnoqda/caabuqa. Ballaarinta degdegga ah ee xooggan ee unugyada CAR-T ee aan lahayn sunta daran waxay muujineysaa astaanta badbaadada wanaagsan ee badeecada iyo dhaqdhaqaaqa xooggan ee ka hortagga burooyinka - xitaa bukaan da' ah oo leh astaamo molecular oo khatar sare leh.